New Hope For Those Battling A Genetic Disease

Young couple with their infant child

An effort is under way to combat a rare genetic disorder that results in the abnormal development of a child’s teeth, hair and skin.

(NAPSI)—There’s hopeful news for those who are at risk for a rare disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations.

A biotechnology company is committed to finding a treatment and is working toward delivering a significant improvement in the health and quality of life to future generations living with this rare genetic disorder.

The Disease

X-linked hypohidrotic ectodermal dysplasia, or XLHED, is the disease and the company is Edimer Pharmaceuticals.

XLHED is a rare genetic disorder that results in abnormal development of teeth, hair and glandular structures in the skin and mucosal membranes.

Patients affected by the disease often contend with lifelong dental issues, respiratory infections, scaly skin, premature hair loss and other related health complications associated with lack of functional sweat and secretory glands.

A Potential Treatment

Edimer is developing EDI200 as a potential treatment for future generations living with XLHED.

In preclinical studies, EDI200 has been shown to greatly enhance the development of hair, teeth, skin and some glandular structures. The studies also indicate early treatment may result in a lifelong benefit.

Clinical trials in humans are currently under way:

• Phase 1 of the adult safety study was completed in spring of 2013.

• Phase 2, the newborn XLHED clinical study, began enrolling applicants in the late summer of 2013 and is ongoing.

For a list of active studies on the disease and the status of each, visit www.clinicaltrials.gov.

Ways To Get Involved

Those who wish to get involved in the clinical study process can register at XLHEDnetwork.com.

To learn more, you can find and follow the company on Facebook.com/EdimerPharma or visit the company’s website at www.edimerpharma.com.

Those who wish to qualify for free genetic testing to see if they are at risk can visit Have the Conversation at www.havetheconvo.com.

For information on the clinical trial process or to participate, contact Ramsey Johnson at ramsey@edimerpharma.com.

Comments are closed.